Dabigatran, ROCKET atrial fibrillation, and beyond basic science, mechanisms of agents, monitoring, and reversal

Stroke

Volumn 44, Issue SUPPL. 1, 2013, Pages

  Bauer, Kenneth A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; International normalized ratio; Prothrombin time; Rivaroxaban; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450 INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; FRESH FROZEN PLASMA; GLYCOPROTEIN P INHIBITOR; PRODRUG; PROTHROMBIN COMPLEX; PROTON PUMP INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; ENCAPSULATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBIN TIME; TREATMENT OUTCOME; VEIN THROMBOSIS;

APIXABAN; ATRIAL FIBRILLATION; DABIGATRAN; INTERNATIONAL NORMALIZED RATIO; PROTHROMBIN TIME; RIVAROXABAN; VITAMIN K ANTAGONISTS;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; CEREBRAL HEMORRHAGE; FACTOR XA; HUMANS; MONITORING, PHYSIOLOGIC; MORPHOLINES; PRODRUGS; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THIOPHENES; THROMBIN; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84880255118     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000387     Document Type: Conference Paper

References (13)

1. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30:1885-1889.
2. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate- A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
3. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57.
4. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011;9(suppl 1):12-19.
5. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49:761-772.
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
8. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-983.
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
10. Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125:159-164; discussion 164.
11. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation. 2012;125:165-170; discussion 170.
12. Bauer KA. Reversal of antithrombotic agents. Am J Hematol. 2012;87(suppl 1):S119-S126.
13. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.